Categories
Change Password!
Reset Password!
Low back pain (LBP) is a condition occurred often and costly to manage.
Chronic low back pain (LBP) occur without
structural causes and are often resistant to conventional analgesic drugs. The
number of pharmacological analgesic drugs is available to reduce the LBP, but
due to their adverse effects, they are unable to provide sufficient therapeutic
effect. Therefore, the results of this research demonstrate that periarticular
injection of meloxicam is significantly reduced the LBP and leads to an
improvement in the level of physical activity after three months’ follow-up.
Low back pain (LBP) is a condition occurred often and
costly to manage. The study involved the estimation of the hypothesis that
Meloxicam periradicular injections might improve physical activity and reduce
LBP than saline injection at three months’ follow-up.
A total of eighty participants with LBP of <6 months
duration were randomized to the Meloxicam or the control after the IRB
approval. The case was crossed-over to the other group if the numeric rating
score (NRS) at 24 hours remained >50% of the pre-treatment score. The NRS
for a successful therapy was <3 at three months’ follow-up. The estimation
of physical-assistance, physical-activities limitations, work-absence, and
pain-related insomnia were taken as secondary outcomes.
The M group and C group exhibited 9.2 and 9.3 baseline
NRS, respectively. After 24hours postoperative follow-up, M group and C group
showed 3.5, and 6.3 mean NRS, respectively. C-group exhibited a higher number
of cross-over cases. Sixty-six patients allocated in the M-group and 54
reported NRS score <3. Whereas only 14 (9+5) subjects continued in the
C-group and 8 patients had NRS <3.
Meloxicam is an efficient analgesic approach for acute/subacute LBP,
and its novel use leads to an escalation in the level of physical activity at
the three months follow-up.
Minerva Anestesiol. 2018 Feb 5.
Treatment of recent onset low back pain with periradicular injections of meloxicam: a randomized, double blind, placebo controlled cross-over study.
Borghi B et al.
Comments (0)